BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 36.3% from the November 15th total of 1,350,000 shares. Based on an average daily volume of 5,810,000 shares, the days-to-cover ratio is presently 0.3 days.

BioVie Price Performance

BIVI traded up $0.05 on Friday, hitting $2.64. 1,861,319 shares of the stock were exchanged, compared to its average volume of 1,685,683. The firm has a market capitalization of $46.91 million, a price-to-earnings ratio of -0.23 and a beta of 0.40. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10. The business has a 50-day moving average of $2.57 and a two-hundred day moving average of $1.81.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings results on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.